Key facts
- It has raised $3.7M; the latest was Early Stage VC ($3.7M) in Dec 2024.
- Notable investors include Enterprise Ireland.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Isovasc Medical (Drug Delivery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Isovasc Medical (Drug Delivery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Isovasc Medical (Drug Delivery)
Operator of an interventional oncology-focused drug-delivery platform intended for the targeted treatment of solid tumors. The company's platform offers proprietary local drug-delivery devices leveraging vascular access and isolated perfusion techniques to deliver novel targeted therapies directly to cancerous tissue, enabling oncology clinicians and healthcare providers to address high unmet medical needs while aiming to improve therapeutic outcomes and quality of life for cancer patients across diverse solid cancer indications.
- Sector
- Healthcare
- HQ
- Galway, Ireland
- Founded
- 2024
- Ownership
- Privately Held (backing)
Isovasc Medical (Drug Delivery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Isovasc Medical (Drug Delivery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Isovasc Medical (Drug Delivery) in its N-PORT filings yet. We sweep new filings monthly.